Mechanism-Based Treatment Strategies for IBD: Cytokines, Cell Adhesion Molecules, JAK Inhibitors, Gut Flora, and More by Schreiner, Philipp et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2019
Mechanism-Based Treatment Strategies for IBD: Cytokines, Cell Adhesion
Molecules, JAK Inhibitors, Gut Flora, and More
Schreiner, Philipp ; Neurath, Markus F ; Ng, Siew C ; El-Omar, Emad M ; Sharara, Ala I ; Kobayashi,
Taku ; Hisamatsu, Tadakazu ; Hibi, Toshifumi ; Rogler, Gerhard
Abstract: Background Although TNF inhibitors revolutionized the therapy of inflammatory bowel disease
(IBD), we have been reaching a point where other therapies with different mechanisms of action are
necessary. A rising number of elderly IBD patients with contraindications to established therapies and a
growing group of patients losing response to anti-TNF therapy compel us to find safer, better-tolerated,
and, ideally, personalized treatment options. However, in order to choose the right drug to fit a patient, it
is indispensable to understand the pathomechanism involved in IBD. Summary The aim of this review is
to explain the inflammatory signaling pathways in IBD and how to inhibit them with current and future
therapeutic approaches. Next to biologic agents targeting inflammatory cytokines (anti-TNF agents, anti-
IL-12/-23 agents, and specific inhibitors of IL-23), biologics blocking leukocyte trafficking to the gut (anti-
integrin antibodies) are available nowadays. More recently, small molecules inhibiting the JAK-STAT
pathway (JAK inhibitors) or preventing lymphocyte trafficking (sphingosine-1-phosphate modulators)
have been approved or are under investigation. Furthermore, modifying the microbiota has potential
therapeutic effects on IBD, and autologous hematopoietic or mesenchymal stem cell transplantation may
be considered for a highly selected group of IBD patients. Key Message Physicians should understand
the different mechanisms of action of the potential therapies for IBD to select the right drug for the right
patient.
DOI: https://doi.org/10.1159/000500721
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-178713
Journal Article
Published Version
Originally published at:
Schreiner, Philipp; Neurath, Markus F; Ng, Siew C; El-Omar, Emad M; Sharara, Ala I; Kobayashi, Taku;
Hisamatsu, Tadakazu; Hibi, Toshifumi; Rogler, Gerhard (2019). Mechanism-Based Treatment Strategies
for IBD: Cytokines, Cell Adhesion Molecules, JAK Inhibitors, Gut Flora, and More. Inflammatory
Intestinal Diseases, 4(3):79-96.
DOI: https://doi.org/10.1159/000500721
Review Article
Inflamm Intest Dis 2019;4:79–96
Mechanism-Based Treatment Strategies for 
IBD: Cytokines, Cell Adhesion Molecules, JAK 
Inhibitors, Gut Flora, and More
Philipp Schreiner a    Markus F. Neurath b    Siew C. Ng c    Emad M. El-Omar d    
Ala I. Sharara e    Taku Kobayashi f    Tadakazu Hisamatsu g    Toshifumi Hibi f    
Gerhard Rogler a    
a
 Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland; b Medizinische 
Klinik 1, Universitätsklinikum Erlangen-Nürnberg, Erlangen, Germany; c Department of Medicine and Therapeutics, 
Institute of Digestive Disease, LKS Institute of Health Science, State Key Laboratory of Digestive Disease, The 
Chinese University of Hong Kong, Hong Kong, China; d St. George and Sutherland Clinical School, University of New 
South Wales, Sydney, NSW, Australia; e Division of Gastroenterology, Department of Internal Medicine, American 
University of Beirut, Beirut, Lebanon; f Center for Advanced IBD Research and Treatment, Kitasato University Kitasato 
Institute Hospital, Tokyo, Japan; g 3rd Department of Internal Medicine, Kyorin University, Tokyo, Japan
Received: February 23, 2019
Accepted: May 2, 2019
Published online: July 9, 2019
Prof. Dr. med. Gerhard Rogler
Department of Gastroenterology and Hepatology
University Hospital Zurich, Rämistrasse 100
CH–8091 Zurich (Switzerland)
E-Mail gerhard.rogler @ usz.ch
© 2019 S. Karger AG, Basel
E-Mail karger@karger.com
www.karger.com/iid
DOI: 10.1159/000500721
Keywords
Biologics · Crohn’s disease · Inflammatory bowel disease · 
Small molecules · Ulcerative colitis
Abstract
Background: Although TNF inhibitors revolutionized the 
therapy of inflammatory bowel disease (IBD), we have been 
reaching a point where other therapies with different mech-
anisms of action are necessary. A rising number of elderly IBD 
patients with contraindications to established therapies and 
a growing group of patients losing response to anti-TNF 
therapy compel us to find safer, better-tolerated, and, ide-
ally, personalized treatment options. However, in order to 
choose the right drug to fit a patient, it is indispensable to 
understand the pathomechanism involved in IBD. Summa-
ry: The aim of this review is to explain the inflammatory sig-
naling pathways in IBD and how to inhibit them with current 
and future therapeutic approaches. Next to biologic agents 
targeting inflammatory cytokines (anti-TNF agents, anti-
IL-12/-23 agents, and specific inhibitors of IL-23), biologics 
blocking leukocyte trafficking to the gut (anti-integrin anti-
bodies) are available nowadays. More recently, small mole-
cules inhibiting the JAK-STAT pathway (JAK inhibitors) or 
preventing lymphocyte trafficking (sphingosine-1-phos-
phate modulators) have been approved or are under inves-
tigation. Furthermore, modifying the microbiota has poten-
tial therapeutic effects on IBD, and autologous hematopoi-
etic or mesenchymal stem cell transplantation may be 
considered for a highly selected group of IBD patients. Key 
Message: Physicians should understand the different mech-
anisms of action of the potential therapies for IBD to select 
the right drug for the right patient. © 2019 S. Karger AG, Basel
Introduction
In recent years, our understanding of the pathogen-
esis of inflammatory bowel disease (IBD) with its two 
main entities, ulcerative colitis (UC) and Crohn’s dis-
ease (CD), has increased considerably. IBD is a chronic 
inflammatory disease believed to be triggered by spe-
cific or multiple environmental factors in genetically 
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susceptible individuals. An impaired mucosal barrier 
together with disturbed luminal microbiota finally lead 
to a consecutive dysregulation of the intestinal immune 
system [1].
Although current strategies connect this knowledge of 
disease pathogenesis with new mechanisms of action for 
potential therapies, there is still no cure in sight. Instead, 
a global increase in the incidence and prevalence of IBD 
can be observed [2, 3], which is mainly driven by higher 
incidence rates in Asian and South American countries 
and due to a demographic shift with a growing, older IBD 
population [4], inevitably leading to a higher prevalence. 
Despite the fact that the course of elderly-onset IBD is 
often mild and associated with a lower use of immuno-
suppressants [5, 6], these IBD patients represent a diffi-
cult-to-treat patient group with many aspects to be con-
sidered [7].
Interestingly, the incidence of IBD in Western coun-
tries – after a tremendous rise in the past 50 years [8] – 
finally seems to increase more slowly or reach a plateau. 
Nevertheless, IBD has still the highest incidence and 
prevalence (exceeding 0.3%) in North America, Oceania, 
and Europe [3, 9]. As mentioned above, we experience an 
increase in the incidence of IBD in Asian countries [3, 8, 
10]. Considering China with a population of nearly 1.4 
billion and India with 1.3 billion people, the increase in 
IBD in these countries [11–14] creates huge economic 
challenges. However, it also provides the opportunity to 
better understand the epidemiological aspects of IBD and 
to investigate the factors that lead to IBD, which finally 
may help us to develop new therapies.
This review highlights novel therapies for CD and UC 
based on novel insights into the highly complex patho-
genesis of IBD, including anti-cell adhesion molecules; 
therapies capable of blocking proinflammatory cytokines 
and stopping downstream signaling; molecules prevent-
ing lymphocyte trafficking; and strategies influencing the 
microbiota and stem cell therapy. The available agents 
and therapies under investigation are summarized in 
Table 1.
Cytokines
TNF Inhibitors
The proinflammatory cytokine TNF-α plays a major 
role in the immunopathogenesis of IBD [15]. In IBD, the 
production of soluble and membrane-bound TNF is sig-
nificantly increased through CD14+ macrophages, fibro-
blasts, and T cells [16].
At the turn of the millennium, the advent of inflix-
imab, a chimeric antibody against TNF comprising 25% 
murine sequence and 75% human sequence, marked an 
important milestone in the therapy for refractory IBD. In 
1997, Targan et al. [17] published the first controlled 
study demonstrating the efficacy of infliximab in CD pa-
tients. More placebo-controlled trials of CD [18, 19] and, 
later on, of UC [20] followed, so that nowadays infliximab 
is a mainstay of IBD therapy particularly for patients who 
do not respond to conventional therapies [21]. In the past 
decade, three other subcutaneous TNF inhibitors have 
become available. Adalimumab, a fully human monoclo-
nal antibody, has been shown to induce and maintain re-
mission in moderate-to-severe CD [22–24] and UC [25–
27]. For certolizumab, a humanized Fab (antigen-binding 
fragment) lacking the fragment crystallizable (Fc) region, 
successful induction and remission could be demonstrat-
ed in CD [28, 29] – and, likewise, for golimumab, a fully 
human antibody, in UC [30, 31]. 
No randomized controlled trials (RCTs) of certoli-
zumab in UC or golimumab in CD have been published. 
However, in the last years some retrospective studies have 
demonstrated the efficacy and safety of golimumab in CD 
[32, 33]. Furthermore, the first results of an open-label 
maintenance study with certolizumab pegol showed its 
effectiveness in UC [34], and a phase II study is still on-
going [35]. Recently, meta-analyses have confirmed the 
efficacy of TNF inhibitors in CD and UC [36–38]. 
Interestingly, etanercept – a soluble recombinant TNF 
receptor also binding to circulating TNF, thereby neutral-
izing it – failed to show efficacy in CD, leading to the con-
cept that the therapeutic effect of anti-TNFs in IBD must 
be due to mechanisms other than only TNF neutraliza-
tion [39]. One explanation for this finding is that both 
membrane-bound and soluble TNF need to be neutral-
ized to induce T-cell apoptosis in vivo. Blocking soluble 
TNF alone, as postulated for etanercept, has no therapeu-
tic effect on IBD [16, 40]. However, it has never been in-
vestigated in detail whether a soluble TNF receptor fails 
to block membrane-bound TNF.
In summary, it has to be admitted that the exact mech-
anism of action of anti-TNF agents in IBD is not fully 
understood. It is generally assumed that inhibition of the 
membrane-bound TNF/TNFR2 pathway is crucially in-
volved in inducing T-cell apoptosis [41], consequently 
 inhibiting downstream proinflammatory pathways.
Although TNF inhibitors revolutionized the treatment 
of IBD, it must be remembered that more than a third of 
patients are primary nonresponders [42] and that the 
 annual risk for loss of response (LOR) is about 13% per 
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patient-year of treatment with infliximab and around 
20% per patient-year [43] with adalimumab. Eventually, 
around 40% of initial responders will definitively lose re-
sponse to infliximab [44]. Even though we can counteract 
immunogenicity as the key mechanism in primary non-
response and LOR by combining infliximab with azathio-
prine [45, 46], by increasing the dose [47], or by shorten-
ing the treatment interval [48], many other unsolved 
problems remain with TNF inhibitors and their short- 
and long-term treatment efficacy.
One major concern is the economic burden of biolog-
ics. Nowadays, two biosimilars of infliximab, CT-P13 (In-
flectra; Remsima) and SB2 (Flixabi), are on the market 
with an approximately 30% lower price than that of the 
reference product [49]. Since biosimilars are manufac-
tured with a different cell line and the manufacturing 
technique may differ slightly from its original product, 
they are highly similar copy versions of the originators, 
but not identical. This slight discrepancy between bio-
similars has raised substantial caution about their use 
[50]. In recent years, more real-life data have become 
available demonstrating no significant differences in ef-
ficacy or safety between biosimilars and their reference 
product [51–53]. A large French equivalence cohort study 
investigating more than 5,000 CD patients confirmed the 
equivalent effectiveness of CT-P13 and infliximab [54]. 
Table 1. Available agents and therapies for Crohn’s disease and ulcerative colitis under investigation
Crohn’s disease Ulcerative colitis Remarks
Cytokines
TNF inhibitors
Infliximab
Adalimumab
Certolizumab
Golimumab
Etanercept
✓
✓
✓
(✓)*
Not effective
✓
✓
Phase II trial ongoing
✓
No data
* Retrospective studies in Crohn’s disease
IL-23/Th17
Ustekinumab
Risankizumab
Brazikumab
Mirikizumab
✓
✓ (phase II)
✓ (phase II)
Phase II trial ongoing
Phase III trial ongoing
Phase III trial ongoing
Phase II trial ongoing
✓ (phase II)
IL-17
Secukinumab Not effective* No data * Even higher Crohn’s disease activity with secukinumab
IL-6
Tocilizumab
PF-04236921
Not effective*
✓ (phase II)* * Only clinical response* Higher rates of perforation
PDE4 inhibitor
Apremilast No data ✓ (phase II)
JAK inhibitors
Tofacitinib
Filgotinib
Upadacitinib
Peficitinib
Not effective (phase II)
✓*
✓ (phase II)
No data
✓
Phase III trial ongoing
Phase III trial ongoing
Not effective* * Mucosal healing comparable to that with placebo* Trends for increased remission and response
Anti-trafficking therapies
Anti-cell adhesion
Natalizumab
Vedolizumab
Etrolizumab
Abrilumab
✓
✓
Phase III trial ongoing
Not effective (phase II)
No data (only one open-label trial)
✓
✓ (phase II)
✓ (phase II)
Increased risk of PML
Anti-MAdCAM-1
PF-00547659 Not effective* ✓ (phase II) * High placebo clinical response and remission rates
Small-molecule integrin antagonists
AJM300
PTG-100
Not effective
No data
✓
Phase II trial stopped Study discontinued due to futility-based outcome
S1P receptor modulators
Ozanimod
Etrasimod
Phase III trial ongoing
No data
✓ (phase II)
✓ (phase II)
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Furthermore, switching from the infliximab originator to 
CT-P13 can be conducted safely and feasibly without 
having to expect more serious adverse events [55–58]. 
Based on the growing number of data on IBD patients 
treated with biosimilars, the European Crohn’s Colitis 
Organisation (ECCO) states that switching from the orig-
inator to a biosimilar in IBD patients is acceptable [59]. 
Currently, many more biosimilars of adalimumab and 
infliximab are in the pipeline [49].
Besides the abovementioned immunogenicity and the 
substantial costs, the two most feared concerns regarding 
anti-TNF therapy are deleterious adverse events, particu-
larly serious or opportunistic infections and malignancy. 
Especially in combination therapy with azathioprine, but 
also less pronounced with anti-TNF monotherapy, there 
exists a nonnegligible risk of lymphoma [60]. Further-
more, the risk of serious infections in anti-TNF-treated 
patients is significantly increased [61, 62] and develops at 
around an annual rate of 2% [63]. The risk is even higher 
with combination therapy [62] and in elderly patients 
above 65 years of age, where the absolute risk can be 2- to 
3-fold greater than in younger patients [62]. Compared 
to patients without immunosuppression, the risk of op-
portunistic infection is approximately 2- to 3-fold in-
creased [64, 65], which is comparable to the infection risk 
with corticosteroids [64].
Newer biologics and small molecules with a better 
safety profile and the possibility of being used as “rescue” 
treatments have been developed and are described below.
IL-23/Th17 Pathway
Recent concepts of the pathophysiology of IBD sug-
gest a disturbed adaptive immune response, with an ex-
cessive Th1 immune reaction especially in CD; it is dis-
cussed that this is induced by IL-12, leading to the pro-
duction of large amounts of interferon-γ (IFN-γ), TNF, 
and IL-6. In contrast, UC is considered a Th2 immune 
response, with an increased release of IL-5, IL-6, IL-13, 
and TNF [66]. More recent data have implicated the in-
nate immune system and the IL-23/Th17 axis as being 
pivotal to the pathogenesis of IBD. A genetic variant of 
IL23R, the gene encoding a subunit of a receptor for IL-
23, which is a cytokine involved in the differentiation of 
Th17 cells, has been found to be significantly associated 
with CD [67]. Activation of IL-23, with its subunits p19 
and p40, triggers the differentiation of naïve T cells into 
Th17 cells, which then produce IL-17A, IL-17F, and IL-
21, thereby suppressing regulatory T-cell activity [16]. 
Th17 cells are considered to build a bridge between the 
adaptive and the innate immune system [68]. Interest-
ingly, apoptosis-resistant IL-23R-positive T cells expand 
in anti-TNF-refractory patients, leading to the hypothesis 
that IL-23 antagonists are suitable agents for anti-TNF-
refractory patients [69].
Next to activation of the IL-23/Th17 pathway through 
antigen-presenting cells, the induction of other members 
of the IL-12 family (consisting of IL-12, IL-23, IL-27, and 
IL-35) [16] is upregulated in intestinal inflammation. Of 
special interest in CD is IL-12, composed of the subunits 
p35 and p40, which induces the differentiation of naïve T 
cells into Th1 cells with concomitant production of TNF 
and IFN-γ [70]. Several agents interfering with the path-
ways of IL-23/IL-12 have been developed or are under 
investigation and show promising results, especially in 
CD patients. In contrast, attempts to inhibit IL-17A or 
IL-17R in IBD have remained unsuccessful.
Ustekinumab is a fully human IgG1 monoclonal anti-
body that blocks the p40 subunit of IL-12/IL-23. Al-
though a phase IIa induction trial failed to show any su-
periority of ustekinumab over placebo regarding clinical 
response at week 8 in moderate-to-severe CD (49 vs. 40%, 
p = 0.340), interestingly, in patients who were infliximab 
experienced, the clinical response was stronger with 
ustekinumab than with placebo (59 vs. 26%, p = 0.022) 
[71]. The phase III trial (CERTIFI) demonstrated a stron-
ger clinical response in patients receiving 6 mg of 
ustekinumab per kilogram body weight (39.7 vs. 23.5%, 
p = 0.005), but the rate of clinical remission did not differ 
significantly between the groups. Furthermore, patients 
who responded to ustekinumab in the induction phase 
had increased rates of response and remission in mainte-
nance therapy with ustekinumab [72]. The UNITI-1 
(TNF antagonist failures) and UNITI-2 (conventional 
therapy failures) trials confirmed the previously pub-
lished data with even better results particularly for anti-
TNF-experienced patients, showing significant efficacy 
in inducing a clinical response in moderately to severely 
active CD and maintaining remission in patients re-
sponding to induction therapy [73]. More recent data 
support the high maintenance rates in IM-UNITI (a 
phase III ustekinumab maintenance study in patients 
with CD) through week 92 without occurrence of serious 
adverse events, confirming its long-term efficacy and 
safety in CD patients [74]. A recently performed substudy 
demonstrated a reduced simplified endoscopic activity 
score for CD at week 8 and week 44 [75]. Maintenance 
trough levels of ustekinumab above 4.5 μg/mL after at 
least 26 weeks of therapy were associated with a stronger 
endoscopic response (75.9 vs. 40.7%, p = 0.008) and a low-
er mean level of C-reactive protein (12.6 vs. 23.9 mg/L, 
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p = 0.040) [76]. Furthermore, ustekinumab induced a fa-
vorable clinical response after 6 months of therapy in a 
refractory population with chronic pouchitis and CD of 
the pouch [77]. The first results of a phase III trial showed 
promising results in moderate-to-severe active UC pa-
tients treated with ustekinumab [78].
With risankizumab, a humanized monoclonal IgG1 
antibody that selectively targets the p19 subunit of IL-23, 
another agent influencing the IL-23 signaling pathway is 
under investigation. The promising results of a random-
ized, double-blind, phase II study in patients with mod-
erate-to-severe CD, in whom over 70% of the patients had 
previously received at least two anti-TNF agents, showed 
higher clinical and endoscopic remission rates (31 vs. 
15%, p = 0.049, and 17 vs. 3%, p = 0.002, respectively) [79]. 
The extension study confirmed the efficacy of risanki-
zumab in maintaining clinical remission at week 52 and 
suggests that extended treatment of patients not in deep 
remission at week 12 increases clinical response and re-
mission rates at week 26 [80]. The most serious adverse 
events were of gastrointestinal origin [79, 80].
Similar to risankizumab, brazikumab (MEDI2070, 
formerly AMG 139) is a monoclonal antibody binding 
selectively to the p19 subunit of IL-23. The first results of 
a phase IIa study in moderate-to-severe CD patients who 
failed treatment with an anti-TNF antibody are promis-
ing. In the brazikumab group, significantly higher rates 
of clinical improvement at week 8 could be demonstrated 
than in the placebo group (49.2 vs. 26.7%, p = 0.010) [81].
Although the IL-23 axis is thought to be mainly in-
volved in CD, the first results of a completed induction 
phase of a phase II study with mirikizumab (LY3074828), 
a p19-directed anti-IL-23 antibody, showed positive re-
sults regarding clinical response and remission at week 12 
in moderate-to-severe UC patients [82]. These results 
have to be confirmed in further studies, but they are en-
couraging with regard to enlarging the armamentarium 
for the treatment of UC.
Anti-IL-17
Despite overexpression of IL-17 in CD tissue [83], a 
known risk polymorphism of IL23R associated with CD 
[67], and the effect of anti-IL-17 agents in other inflam-
matory diseases [84, 85], a proof-of-concept study failed 
to show any efficacy of secukinumab, an IL-17 inhibitor, 
in CD patients. Patients treated with secukinumab suf-
fered from higher CD activity than patients treated with 
placebo [86]. Furthermore, some recently published case 
reports presented the emergence of IBD in patients treat-
ed with secukinumab [87]. This deleterious effect with an 
anti-IL-17 antibody on CD has shown the limitations of 
our understanding of the complex system of cytokines 
involved in the pathogenesis of IBD. Nowadays, it is as-
sumed that besides a possible proinflammatory effect, IL-
17 acts as an important cytokine for homeostasis in the 
gut, plays a role in wound repair [88], and maintains in-
testinal barrier integrity [89]. Blockade of IL-17 can sub-
sequently result in an altered integrity of the gut barrier, 
which has a more substantial impact on causing colitis 
than the proinflammatory effect of IL-17 [90].
Anti-IL-6
Due to the fact that IL-6 possesses multiple proinflam-
matory effects and its production is upregulated in pa-
tients with CD [16], it is another potential target for the 
treatment of IBD. Interestingly, the IL-6 pathway could 
be a loophole in patients refractory to anti-TNF and anti-
integrin therapy. A study investigating biomarkers of ve-
dolizumab (VDZ) resistance demonstrated that patients 
with IBD failing anti-TNF and VDZ treatment had sig-
nificantly higher circulating IL-6 levels [91]. Therefore, it 
is thought that the IL-6 pathway can cause inflammation 
independently of TNF.
Tocilizumab, a humanized monoclonal antibody 
against the IL-6 receptor already used in rheumatoid ar-
thritis [92], has been investigated in a randomized pilot 
trial in active CD, demonstrating a higher clinical re-
sponse rate than placebo (80 vs. 31%, p = 0.019), but nei-
ther endoscopic nor histological healing [93]. Since the 
performance of this small study, no further trials of tocili-
zumab in CD were performed. 
Another fully human IgG2 monoclonal antibody 
binding and neutralizing IL-6 is PF-04236921. In a dou-
ble-blind, parallel-group trial in CD patients who failed 
anti-TNF therapy (ANDANTE I and II), PF-04236921 
appeared to be efficient in inducing a clinical response 
and remission at week 12 (47.4 vs. 28.6%, p < 0.050, and 
27.4 vs. 10.9%, p < 0.050, respectively) [94]. However, it 
should be noted that gastrointestinal abscesses and perfo-
ration were observed with PF-04236921, a known serious 
adverse event that has also been reported for tocilizumab 
[95]. Although most of the perforations occurred in pa-
tients having diverticulitis and previously taking nonste-
roidal anti-inflammatory drugs [96] (therefore being ex-
cluded from the ANDANTE trial), the occurrence of per-
foration was still present [94]. This disastrous event, 
especially in patients already suffering from a gastrointes-
tinal disease, may compromise a wide spread of IL-6 an-
tagonists and requires special attention in future clinical 
trials.
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Another therapeutic target in TNF-refractory patients 
is oncostatin M (OSM). OSM belongs to the family of IL-6 
cytokines and is highly expressed in active CD and UC 
patients, particularly with deep ulcerations. Furthermore, 
a mouse model demonstrated high expression of OSM in 
TNF-resistant inflamed intestinal mucosa [97]. This find-
ing could lead to a possible new biomarker for therapy 
responsiveness to TNF treatment, or to a new treatment 
option.
Anti-IL-9
A further interesting approach is to block IL-9 as a 
therapeutic target in IBD. Patients with UC have elevated 
IL-9-expressing T cells and cells expressing the transcrip-
tion factor PU.1, a key regulator of Th9-cell differentia-
tion. An animal model demonstrated the same findings 
and could show that IL-9- and PU.1-deficient mice were 
spared from developing colitis [98]. Therefore, it is as-
sumed that IL-9 negatively alters intestinal barrier func-
tion by influencing tight junction molecules [99]. These 
findings can be used in the development of a new treat-
ment option for UC.
Phosphodiesterase 4 Inhibitor
Phosphodiesterase 4 (PDE4) is a protein highly ex-
pressed in immune cells which catalyzes the breakdown 
of cyclic AMP (cAMP). cAMP is a key player in the intra-
cellular inflammatory cascade [100], and elevated intra-
cellular cAMP levels suppress the production of various 
proinflammatory mediators [101] and promote the re-
lease of anti-inflammatory mediators [102]. By blocking 
PDE4, cAMP levels rise, which subsequently results in an 
anti-inflammatory response [100]. Apremilast is an oral-
ly administered PDE4 inhibitor showing anti-inflamma-
tory activity in murine models of colitis through reducing 
TNF-α, IFN-γ, IL-6, IL-13, and IL-9 [103]. A phase II tri-
al with active UC patients treated with apremilast showed 
an improvement in symptoms, biomarkers, endoscopy 
results, and mucosal healing compared to placebo at week 
12 [104].
Janus Kinase Inhibitors
Janus kinases (JAKs) play a central role in innate and 
adaptive immune response. Since nearly all cytokines use 
the JAK signal transducer and activator of transcription 
(STAT) pathway as a common signaling pathway, JAK 
inhibitors block the activity of multiple cytokines simul-
taneously. Cytokines not using the JAK-STAT pathway 
are TNF, IL-1, IL-8, TGF-β, and macrophage colony-
stimulating factor [105]. 
After binding of a cytokine to its cell surface receptor, 
the intracellular part of JAK gets activated. Subsequently, 
JAKs phosphorylate the intracellular part of the cytokine 
receptor, which allows binding of latent cytoplasmic tran-
scription factors known as STATs. These in turn become 
tyrosine phosphorylated by the JAKs, dimerize, and 
translocate to the nucleus to regulate gene expression 
[106]. Four JAKs are found in humans, namely, JAK1, 
JAK2, JAK3, and tyrosine kinase 2 (TYK2), as well as 
 seven STATs, that is, STAT1, STAT2, STAT3, STAT4, 
STAT5A, STAT5B, and STAT6 [106].
JAK inhibitors are small molecules which differ from 
antibodies or other biologicals in many ways. Unlike bio-
logicals, small molecules have a short half-life, allowing 
interference with the immunosuppressive effect in case of 
infection, surgery, or pregnancy. Furthermore, they are 
efficient at lower doses; thus, they do not block the entire 
signaling pathway [107]. Patients often prefer orally ad-
ministered medication over an injectable therapy [108]; 
hence, small molecules could improve patient acceptance 
and may increase adherence. Lastly, due to their small 
size, they confer a much lower risk of immunogenicity 
and allergic reactions [109, 110].
Tofacitinib, a small molecule, inhibits JAK1 and JAK3, 
as well as, to a lesser extent, JAK2 and TYK2, which is why 
it is considered as pan-JAK inhibitor. JAK1/JAK3 dimer-
ization controls signaling of the cytokines IL-2, IL-4, IL-7, 
IL-9, IL-15, and IL-21 [107]. By blocking these signaling 
pathways, B-cell class switching and differentiation of T 
cells and NK cells may be suppressed [107, 111].
After a positive phase II trial in moderate-to-severe 
UC patients [112], three phase III trials with tofacitinib 
(OCTAVE Induction 1 and 2 and OCTAVE Sustain) fol-
lowed, which confirmed its efficacy in induction and 
maintenance therapy compared to placebo in patients 
with moderately to severely active UC [113] (remission at 
week 8 in OCTAVE Induction 1 and 2: 18.5 vs. 8.2%, p = 
0.007, and 16.6 vs. 3.6%, p < 0.001, respectively; remission 
at week 52 in OCTAVE Sustain: 34.6% (5 mg) and 40.6% 
(10 mg) vs. 11.1%, p < 0.001). Observed adverse events 
were herpes zoster infection and increased lipid levels 
[113]. The reason for the significantly higher incidence of 
herpes zoster infection is not known [114]. However, JAK 
inhibitors block the IL-6 signaling pathway, which may 
explain the frequent increase in lipid levels also observed 
with tocilizumab [115], a selective IL-6 antagonist.
A safety analysis up to 8.5 years showed no more ad-
verse events over time than what had been observed in 
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previous studies [116]. It has to be mentioned, though, 
that the US Food and Drug Administration (FDA) re-
cently published a warning after an ongoing safety trial 
had found an increased risk of pulmonary embolism and 
death among patients with rheumatoid arthritis treated 
with 10 mg tofacitinib twice daily [117]. A systematic re-
view of studies on rheumatic arthritis patients treated 
with tofacitinib, however, did not find an increased risk 
for malignancy [118].
Despite the fact that no head-to-head trials exist, a sys-
tematic review suggested that tofacitinib should be ranked 
highest for induction of remission and mucosal healing 
as a second-line agent for patients with moderate-to-se-
vere UC previously treated with an anti-TNF agent [119]. 
Since a recently published study confirmed the rapid on-
set of action with significant improvement already within 
3 days after starting tofacitinib [120], this drug could pos-
sibly be utilized for UC patients in need of a fast-acting 
agent.
In contrast, in moderately to severely diseased CD 
patients treated with tofacitinib, clinical remission rates 
were not significantly different from those with placebo 
in a phase IIb trial [121]. Interestingly, filgotinib, an-
other orally administered JAK inhibitor selectively tar-
geting JAK1, demonstrated a significantly higher rate of 
clinical remission and response in CD patients than pla-
cebo (47 vs. 23%, p = 0.0077, and 59 vs. 41%, p = 0.0453, 
respectively) in a phase II RCT (FITZROY study) [122]. 
Anti-TNF-naïve patients had higher remission and re-
sponse rates than anti-TNF-experienced patients. Nev-
ertheless, endoscopic mucosal healing at week 10 was 
comparable to that in the placebo group. It may be ar-
gued that the optimal timing for endoscopic assessment 
using JAK inhibitors is unknown and the time of endos-
copy at week 10 is too early to observe differences in 
mucosal healing.
Another JAK inhibitor, currently investigated in a 
phase II study on anti-TNF-experienced CD patients, is 
upadacitinib (ABT-494). In this trial, upadacitinib, which 
inhibits JAK1, demonstrated higher rates of clinical re-
sponse, remission, and endoscopic improvement than 
placebo [123]. Although the safety profile was compara-
ble to that of placebo, further studies are needed to con-
firm the safety and efficacy of upadacitinib.
Peficitinib, another oral JAK inhibitor, targets JAK3 
6-fold more frequently than JAK1 and JAK2. In a phase 
IIb trial on patients with moderate-to-severe UC [124], 
peficitinib failed to show a dose response at week 8 ac-
cording to the Mayo score, but trends for increased re-
mission and response rates were observed with doses ≥75 
mg. Since serum and fecal inflammation markers were 
not different from those with placebo, it is doubtful 
whether the peficitinib dose was high enough to reach a 
biological effect.
Further JAK inhibitors under development for IBD 
are BMS-986165 and TD-1473. BMS-986165 is a specific 
Tyk2 inhibitor, blocking the IL-12, IL-23, and Th1 path-
way [125] and is under investigation in an ongoing phase 
II study on moderate-to-severe CD subjects [126].
TD-1473 is a novel orally administered pan-JAK in-
hibitor that selectively inhibits JAK in the gastrointestinal 
tract [127]. In a phase Ib study on patients with moder-
ately to severely active UC, TD-1473 was well tolerated 
and showed low plasma exposure confirming gut selec-
tivity and signals for clinical and biomarker activity [128].
Although the development of JAK inhibitors is still in 
its infancy, our understanding of the JAK-STAT pathway 
is increasing, which could lead to more specific JAK in-
hibitors in the future.
Anti-Trafficking Therapies
Anti-Cell Adhesion Molecules
After activation of the innate and acquired immune 
systems by luminal contents and intestinal microbes, 
multiple inflammatory mediators are released that attract 
further activated immune cells. The perpetuation of the 
inflammatory response in the mucosa is supported by the 
migration of activated lymphocytes and monocytes into 
the inflamed area [1]. Leukocytes roll along the vascular 
endothelium and transmigrate through the endothelium 
to the inflamed mucosa [129]. To achieve adhesion of a 
leukocyte to endothelial cells, interaction between cell-
expressed integrins on the surface of leukocytes and tis-
sue-expressed adhesion molecules is important. The α4β7 
integrins on the surface of leukocytes and the mucosal 
addressin cell adhesion molecule (MAdCAM) on the vas-
cular endothelium play a pivotal role in the migration of 
gut-homing leukocytes. To inhibit local inflammation, 
this pathway may be blocked at many sites by different 
drugs, such as VDZ (specific IgG1 antibody blocking 
α4β7), natalizumab (targeting the α4 subunit of the α4β7 
and α4β1 integrins), etrolizumab (blocks the β7 integrin 
subunit), and MAdCAM inhibitors [111].
Natalizumab, a monoclonal antibody directed against 
the α4 subunit, inhibits gut and brain lymphocyte migra-
tion through blocking α4β7 and α4β1 integrin-mediated 
interactions [130]. Induction therapy failed to show su-
periority of natalizumab over placebo in moderate-to-
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severe CD (ENACT-1 trial, 56 vs. 49%, p = 0.05), but 
demonstrated efficacy in sustaining remission in patients 
who had responded to natalizumab (ENACT-2 trial, 61 
vs. 28%, p < 0.001) [131]. However, a post hoc analysis of 
the ENACT-1 trial showed efficacy in patients with ac-
tive disease. The ENCORE trial confirmed the efficacy of 
natalizumab in inducing remission in patients with mod-
erately to severely active CD and active inflammation 
[132].
A serious adverse event of therapy with natalizumab is 
the occurrence of progressive multifocal leukoencepha-
lopathy (PML) due to JC polyomavirus [131, 133, 134]. 
However, patients unexposed to immunosuppressive 
therapy and negative for JC virus antibodies had a very 
low PML incidence rate of < 0.11 per 1,000 [134].
A recently published Cochrane review suggests the ef-
fectiveness of natalizumab in induction of clinical remis-
sion and response in moderate-to-severe CD [135]. How-
ever, the increased risk of PML and the availability of al-
ternative agents limit its use as second-line medication 
for CD patients. Nevertheless, in retrospective case re-
views, natalizumab was used in difficult-to-treat CD pa-
tients who had previously failed TNF inhibitor treatment, 
and it showed efficacy and safety in these patients [136, 
137]. Therefore, it could still be an option for difficult-to-
treat CD patients and used under a surveillance program 
(TOUCH Prescribing Program) [138]. Another potential 
indication is CD with concomitant multiple sclerosis in 
patients who have never been exposed to immunosup-
pressants [139].
A further anti-integrin antibody is VDZ, a humanized 
monoclonal antibody that blocks the entire α4β7 heterodi-
mer. Compared to natalizumab, VDZ selectively prevents 
leukocyte trafficking to the gut without targeting α4β1 in-
tegrin, which modulates brain trafficking. The GEMINI 
1 and 2 studies demonstrated that VDZ is more effective 
than placebo as induction and maintenance therapy in 
moderate-to-severe UC [140] and CD [141]. In TNF-na-
ïve UC patients, the efficacy is greater than in patients 
who have previously failed TNF antagonist treatment. 
However, it is still an alternative for patients who have 
previously failed TNF antagonist therapy [142]. The same 
results were obtained for CD [143], but the efficacy was 
only statistically superior in previously TNF-treated pa-
tients after 10 weeks of VDZ. This indicates that VDZ 
needs more time to induce a response, especially in previ-
ously TNF-treated patients [143]. Data from the GEMINI 
long-term safety (LTS) study show the long-term efficacy 
and safety of VDZ in maintenance of remission in UC 
[144] and CD [145] over more than 3 years.
The elevated risk of PML with natalizumab was not 
observed under VDZ treatment [144–146], probably be-
cause VDZ does not inhibit α4β1. In addition, due to the 
gut-selective blockade of α4β7, VDZ has an excellent safe-
ty profile without any risk of serious or opportunistic in-
fections [147]. Recently published real-world data sup-
port the safety and efficacy of VDZ, even in refractory 
IBD patients [146, 148], and demonstrate a cumulative 
rate of deep remission in 30% of patients [149–152].
As with all biologicals, VDZ has the potential for im-
munogenicity [153], albeit at a low level with an incidence 
rate of LOR to VDZ of 47.9 per 100 person-years of fol-
low-up in CD and of 39.8 per 100 person-years of follow-
up in UC [154]. Patients who have experienced a LOR to 
an anti-TNF therapy before use of VDZ have a 2-fold in-
creased risk of LOR to VDZ [155]. Interestingly, immu-
nogenicity is higher for anti-TNF antibodies than for 
VDZ [153], but the rate of LOR to VDZ is not lower than 
that to anti-TNF therapy [154]. Among patients with 
LOR to VDZ, shortening of the interval and intensifica-
tion of the dose lead to a clinical response in around 50% 
of patients [154, 155].
Despite a lack of head-to-head trials comparing anti-
TNF and VDZ therapy, its efficacy and safety profile 
makes VDZ an interesting first-line biologic, especially 
for elderly UC patients [156], and can be considered as 
first-line agent for CD patients when safety is more im-
portant than a fast response to therapy [157]. Interest-
ingly, a simulation model regarding the positioning of 
VDZ in IBD therapy predicts the greatest potential ben-
efit in quality-adjusted life-years due to higher remission 
rates when VDZ is used prior to anti-TNF therapy [158]. 
The model therefore considers VDZ as the first-line ste-
roid-sparing medication. However, when choosing the 
most suitable first-line biological, many aspects have to 
be considered. In patients with extraintestinal manifesta-
tion or patients with acute severe colitis requiring a fast 
effect of therapy, anti-TNF treatment probably still is the 
better choice [156, 159]. Although exploratory analyses of 
the data from the GEMINI 2 trial have confirmed the ef-
ficacy of VDZ in fistula closure in patients with fistulizing 
CD [160], robust data regarding this selective group of 
patients are lacking. A recently finished placebo-con-
trolled study will hopefully clarify this unanswered ques-
tion [161].
Etrolizumab is a humanized IgG1 antibody selectively 
targeting the β7 integrin subunit. Besides inhibition of 
leukocyte trafficking to the gut by blocking α4β7/MAd-
CAM-1 interactions, it further blocks αEβ7 E-cadherin in-
teractions, which is believed to be an important mecha-
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nism in retention of lymphocytes in the intraepithelial 
compartment. In a double-blind, placebo-controlled, 
randomized phase II study, etrolizumab achieved clinical 
remission at 10 weeks in a significantly higher number of 
patients with moderate-to-severe UC than did placebo 
(21% [300 mg] vs. 0%, p < 0.010, and 10% [300 mg plus 
loading dose] vs. 10%, p = 0.048) [162]. The side effect 
profile is similar to that of VDZ. Currently, phase III clin-
ical trials are ongoing to confirm the efficacy and safety 
of etrolizumab.
Other than VDZ, abrilumab (AMG 181) is a complete-
ly human antibody against α4β7 integrin. A recently pub-
lished phase IIb trial did not meet the primary endpoint 
(clinical remission at week 8) in patients with moderate-
to-severe CD [163]. In the phase IIb UC study, higher 
rates of remission at week 8, response, and mucosal heal-
ing could be demonstrated [164].
Anti-MAdCAM-1 (PF-00547659)
Anti-MAdCAM-1 is a fully humanized IgG2 anti-
body targeting MAdCAM-1, an intestinal endothelial 
cell adhesion molecule. It prevents gut homing in lym-
phocytes carrying the α4β7 integrin on their surface. The 
phase II TURANDOT trial demonstrated higher remis-
sion rates with PF-00547659 among moderately to se-
verely active UC patients having failed at least one con-
ventional therapy [165]. In contrast, anti-MAdCAM an-
tibody did not reach statistically significant results for 
clinical response in patients with moderate-to-severe 
CD who had previously failed anti-TNF or immunosup-
pressive therapy (phase II OPERA trial), though, unex-
pectedly, high clinical response and remission rates were 
observed with placebo [166]. The most common adverse 
events identified were nasopharyngitis, arthralgia, and 
headache [165].
Small-Molecule Integrin Antagonists
AJM300 is an oral integrin-targeting agent currently in 
the pipeline for treatment of IBD. AJM300 is a small-mol-
ecule inhibitor targeting the α4 integrin subunit [167] and 
was tested in moderately active UC patients in whom 
higher rates of clinical response at week 8, clinical remis-
sion, and even mucosal healing could be demonstrated 
[168]. Available in abstract form only, a randomized, 
double-blind trial demonstrated no significant difference 
in clinical response in active CD patients [169]. Due to the 
shared mechanism with natalizumab in blocking α4 inte-
grin, there is a potential risk of PML. Although the pub-
lished data show the efficacy of AJM300 in UC and have 
not yet demonstrated any risk of PML [168], it remains 
uncertain whether AJM300 will get a foothold in IBD 
treatment algorithms.
Another oral anti-integrin is PTG-100 (an α4β7 antag-
onist peptide). However, a phase IIb study (PROPEL) was 
discontinued following an interim analysis [170].
Sphingosine-1-Phosphate Receptor Modulator
Sphingosine-1-phosphate (S1P) is a signaling mole-
cule that regulates the traffic of lymphocytes out of the 
lymphoid organs into the bloodstream and to inflamed 
tissue. Ozanimod belongs to the group of S1P modula-
tors, which are small molecules downregulating S1P re-
ceptor subtypes 1 and 5 on lymphocytes and prevent 
lymphocyte trafficking out of the lymph nodes to the site 
of inflammation [171, 172]. In a phase II RCT [173] of 
moderate-to-severe UC, ozanimod applied in two doses 
(0.5 and 1.0 mg per day) showed significant improve-
ment in clinical response and remission within the group 
receiving 1 mg ozanimod per day compared to placebo 
(16 vs. 6%, p = 0.048). Although the rate of endoscopic 
remission was significantly higher in both treatment 
groups, no significant difference in histologic remission 
could be observed at week 8. Probably, as with VDZ, the 
onset of action occurs later because lymphocytes already 
present in the inflamed tissue do not get blocked through 
ozanimod. The frequency of severe adverse events was 
comparable to that with placebo. However, findings ob-
served with fingolimod, a nonselective S1P receptor 
modulator, demonstrated multiple adverse events such 
as viral infections [174], bradyarrhythmias [175], macu-
lar edema [176], and respiratory events, which may be 
explained by its specific mode of action as a S1P modula-
tor. Additionally, several cases of PML during treatment 
with fingolimod occurred [177].The long-term safety of 
ozanimod, including the risk of PML, still needs further 
evaluation.
Etrasimod (APD334) is another selective S1P receptor 
modulator under investigation for UC treatment. After 
two randomized double-blind studies on healthy individ-
uals had demonstrated its safety and a rapid decrease in 
T-helper and -naïve cells [178], phase II (randomized, 
double-blind, parallel-group) trials in UC patients were 
recently completed [179, 180]. The first results of the OA-
SIS induction study showed, at week 12, a greater change 
in Mayo score (difference, 0.99 points; 90% CI, 0.30–1.68; 
p = 0.009), a bigger endoscopic improvement (41.8 vs. 
17.8%, p = 0.003), and more patients in clinical remission 
(33.0 vs. 8.1%, p < 0.001) among patients treated with 2 
mg etrasimod compared to a placebo group [181].
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Intestinal Mucosa and Gut Flora
Besides a dysfunction of the adaptive immune system, 
the innate immune response is impaired in IBD. The 
body’s first defense to luminal antigens in the gut consists 
of epithelial cells, which are protected by an adherent, hy-
drophobic mucus layer. This mucus layer is mainly com-
posed of phosphatidylcholine, and to a much lower extent 
of lysophosphatidylcholine, which both show significant-
ly decreased levels in UC patients [182]. This impaired 
mucus layer can lead to increased permeability of the in-
testinal barrier and, consecutively, to mucosal barrier 
dysfunction in IBD patients [183]. After a proof-of-con-
cept study showing the safety of an orally administered 
phosphatidylcholine (LT-02) and its efficacy in induction 
of clinical remission in UC patients compared to placebo 
[184], two further studies followed [185, 186], and a mul-
ticenter trial confirmed these results [187]. Despite previ-
ous positive results, a phase III trial has recently been 
stopped due to lack of efficacy [188]. As the patients in 
this study were taking mesalazine simultaneously with 
phosphatidylcholine, it was hypothesized that the topical 
bioavailability of phosphatidylcholine to the colonic mu-
cus was reduced [189]. Nevertheless, this interesting ap-
proach could evolve into a new effective treatment for UC 
patients, with a favorable safety profile.
Modifying the Microbiota
Patients with IBD have an altered microbiome with a 
reduction of microbial diversity, which is more pro-
nounced in CD than in UC [190]. This low diversity 
comes with low amounts of short-chain fatty acid-pro-
ducing bacteria, higher levels of proteobacteria produc-
ing the endotoxin lipopolysaccharide, and a higher po-
tential for mucus-degrading processes [191–193]. These 
changes can disrupt intestinal barrier integrity and sub-
sequently activate innate immune responses. Therefore, 
interventions aiming at modifying the microbiota of IBD 
patients are under investigation. In addition to the highly 
complex attempt to positively change the microbiota in 
IBD patients through dietary interventions [194, 195], 
various options to alter the microbiota in IBD patients are 
under investigation, namely, administration of probiotics 
and antibiotics as well as fecal microbiota transplantation 
(FMT).
Only a few studies demonstrated a benefit of probiot-
ics for UC patients. Probiotics seem to be effective in 
maintaining remission in UC patients with pouchitis 
treated with VSL#3 [196] and maintaining remission with 
Escherichia coli Nissle [197]. In active CD, probiotics do 
not show any efficacy [198]. Interestingly, probiotic bac-
teria induce human beta defensin 2 [199], which is an en-
dogenous antimicrobial peptide that is part of innate im-
munity. Defensins are produced out of epithelial surfaces, 
“professional phagocytes,” and Paneth cells and regulate 
host immunity in the gastrointestinal tract [200]. Re-
duced levels of alpha defensins are shown in ileal CD and 
reduced levels of beta defensins are seen in colonic CD 
patients [201, 202]. Only recently, a study demonstrated 
that orally administered human beta defensin 2 increased 
the microbiota and significantly improved health in a 
dextran sulfate sodium-induced colitis mouse model 
[203]. This result supports a therapeutic application of 
defensins for IBD patients.
Regarding antibiotics, the data are more limited and 
controversial [204]. Metronidazole plays a role in pro-
phylaxis of postoperative CD [205] or treatment of peri-
anal CD [204] and, like ciprofloxacin, in pouchitis [206].
Another method of altering the gut microbiota of a 
patient is to infuse a fecal solution from a donor via the 
upper or lower gastrointestinal tract of the recipient. 
FMT gained attention due to excellent results in treating 
recurrent Clostridium difficile infections [207, 208]. Many 
case reports and observational studies have suggested a 
favorable outcome when treating refractory UC with 
FMT [209]. Furthermore, a systematic review and meta-
analysis [210], including four RCTs, suggests a significant 
efficacy of FMT in UC compared to placebo. Since the 
only RCT with negative results used a nasoduodenal ap-
proach and only two treatment sessions [211], a repetitive 
colorectal approach is more advisable when treating UC 
with FMT. This could be demonstrated in an RCT on UC 
in which an intensive-dosage FMT (1 infusion at the first 
colonoscopy with following enema 5 days a week for 8 
weeks) was compared to placebo [212]. Steroid-free clin-
ical remission and response could be seen in 44 and 54%, 
respectively, of the FMT-treated patients (vs. 20%, p = 
0.021, and 23%, p = 0.004, in the placebo group). In addi-
tion, the endoscopic response rate was significantly high-
er in the FMT group (32 vs. 10%, p = 0.016), even if there 
was no difference in endoscopic remission rate between 
the two groups (12 vs. 8%, p = 0.48). The currently avail-
able data do not show any difference regarding adverse 
events [210, 212]. It is important to mention that the re-
sponse to FMT in most cases is only temporary, and that 
FMT is not a cure for UC [213].
Although FMT shows promising results, further long-
term studies are needed to support its safety and efficacy 
in treating refractory UC patients.
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Stem Cell Therapy
As a last salvage therapy, for highly selected refractory 
CD patients in whom a surgical procedure is not possible, 
autologous hematopoietic stem cell transplantation 
(AHSCT) may be considered [214]. The concept is to 
 reset the immune system through a conditioning regimen 
that stops inflammation, as well as to restore immune tol-
erance.
The ASTIC trial, a controlled trial of a large cohort of 
refractory CD patients undergoing AHSCT who had 
failed at least three immunosuppressive/biological treat-
ments, demonstrated significant improvement with 
 AHSCT in respect to clinical and endoscopic remission 
1 year after AHSCT. Serious adverse events, including 
one death, occurred due to infections associated with 
pancytopenia induced by the conditioning regimen [215, 
216]. During long-term follow-up over a median time of 
3.4 years, 44% of these highly refractory CD patients with 
multiple previous therapies (a median of 6 previous lines 
of therapy) were still in remission, and 27% of the patients 
required no medical therapy [217]. The mortality risk 
(around 1%) and the rates of infective complications 
(around one-third) seemed to be comparable to those of 
other indications for HSCT. Since the patients with the 
greatest complications were current smokers and patients 
with perianal disease [216, 217], special precautions must 
be taken with regard to this subgroup. For patients with 
an identical twin, an interesting approach regarding safe-
ty issues is syngeneic HSCT instead of AHSCT. Due to 
avoidance of mobilization chemotherapy, the risk of neu-
tropenia and infectious complications can be avoided. 
One case report of a patient with refractory CD treated 
with syngeneic HSCT demonstrated that 4 years after 
transplantation, clinical remission without specific ther-
apy for CD could be possible [218].
Another approach in stem cell therapy is the use of 
mesenchymal stem cells (MSCs) derived from adipose 
tissue or bone marrow for treating refractory perianal fis-
tulas in patients with CD. It could be shown that adipose-
derived MSCs are as efficacious as bone marrow-derived 
MSCs [219–222], which leads to the conclusion that the 
origin of the cells is not that important. An encouraging 
proof-of-concept study in which allogeneic, expanded 
adipose-derived MSCs (Cx601) were locally injected into 
the surrounding tissue of complex perianal fistulas pres-
ent in CD patients [223] supports the hypothesis of anti-
inflammatory and immunomodulatory features of adi-
pose-derived MSCs. Hence, a subsequent phase III ran-
domized, double-blind controlled trial was performed 
[224]. CD patients with complex perianal fistulas treated 
with Cx601 significantly more often achieved the prima-
ry endpoint defined as combined remission (clinical as-
sessment of closure and absence of collections > 2 cm con-
firmed by MRI) at week 24 than those treated with pla-
cebo (51 vs. 36%, p < 0.021) [224]. There were no serious 
adverse events in the Cx601 group. Long-term data over 
1 year confirm the safety and efficacy of Cx601 in fistuliz-
ing CD [225] with a combined remission rate of 56.3% 
(vs. 38.6% in controls; p = 0.010). It is important to men-
tion that patients who were on treatment with anti-TNF 
or another immunosuppressant were to be maintained 
on stable doses during the study. Whether these patients 
could stop their immunosuppression after injection of 
Cx601 was not addressed.
Although there still are some unanswered questions, it 
can be assumed that MSC therapy is a safe and minimal-
ly invasive option for a highly selected group of CD pa-
tients with fistulas unresponsive to biologics.
Conclusions
The anti-TNF era brought hope for the therapy of re-
fractory IBD patients; however, after two decades, several 
problems are still unsolved and new therapies are urgent-
ly needed. Our understanding of the involved cytokines 
and their downstream pathways has helped us to develop 
new treatment strategies with different target points 
within the pathogenesis of IBD. Furthermore, our grow-
ing understanding of genetic factors and the microbiome 
yields further targets for the treatment of IBD and can 
help us in understanding the onset of the disease and, 
thereby, in developing prevention strategies. 
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